Steincares And Shilpa Biologicals Sign Licensing Deal To Expand Biosimilars In Latin America

Steincares and Shilpa Biologicals announced a strategic licensing agreement focused on expanding biosimilar access across Latin America. The partnership combines Shilpa Biologicals’ proven capabilities in biosimilar development and manufacturing with Steincares’ strong distribution network in the region. The initiative is expected to improve affordability and accessibility of biologic therapies, addressing unmet healthcare needs.  

Key Highlights  

• Steincares and Shilpa Biologicals sign licensing agreement for biosimilars  
• Partnership targets expansion across Latin American markets  
• Shilpa Biologicals brings expertise in biosimilar manufacturing and innovation  
• Steincares leverages regional distribution and healthcare networks  
• Focus on improving affordability and accessibility of advanced biologic therapies  

Strategic Impact  
The agreement underscores the growing importance of biosimilars in global healthcare, particularly in emerging markets where affordability remains a challenge. Analysts note that the collaboration positions both companies to capture rising demand for cost-effective biologic treatments in Latin America. By combining manufacturing strength with regional distribution, the partnership enhances patient access, supports healthcare sustainability, and strengthens both firms’ international presence.  

Sources: Reuters, Economic Times, Business Standard